ストックスクリーナーアプリを入手
91.16
1.05%
0.99
前日終値:
$90.17
開ける：
$90.65
24時間の取引高:
661.99K
Relative Volume:
0.12
時価総額：
$132.22B
収益：
$15.91B
当期純損益:
$1.79B
株価収益率:
111.17
EPS:
0.82
ネットキャッシュフロー:
$1.89B
1週間 パフォーマンス:
+4.03%
1か月 パフォーマンス:
+3.49%
6か月 パフォーマンス:
+20.42%
1年 パフォーマンス:
+64.71%
1日の値動き範囲:
$90.23
$91.25
1週間の範囲:
$86.01
$91.18
52週間の値動き範囲:
$53.93
$91.18
Boston Scientific Corp Stock (BSX) Company Profile
名前
Boston Scientific Corp
セクター
電話
508-683-4000
住所
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BSX | 91.16 | 132.22B | 15.91B | 1.79B | 1.89B | 0.82 |
| ABT | 115.67 | 201.34B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 387.57 | 146.32B | 21.97B | 3.59B | 3.21B | 6.74 |
| MDT | 84.38 | 107.39B | 33.00B | 4.29B | 5.50B | 2.71 |
| EW | 69.91 | 41.01B | 6.60B | 4.16B | 490.10M | 2.34 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-01 | アップグレード | Mizuho | Neutral → Buy |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-06-30 | 開始されました | CL King | Buy |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-20 | 再開されました | Citigroup | Buy |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-06 | 開始されました | Wolfe Research | Outperform |
| 2022-05-27 | アップグレード | Needham | Hold → Buy |
| 2022-04-13 | 再開されました | Truist | Buy |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-05-26 | ダウングレード | Needham | Buy → Hold |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-17 | 開始されました | Truist | Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Peer Perform |
| 2020-04-22 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | アップグレード | Goldman | Neutral → Buy |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Buy |
| 2019-12-30 | 繰り返されました | Cowen | Outperform |
| 2019-12-19 | ダウングレード | Needham | Strong Buy → Buy |
| 2019-09-05 | 再開されました | JP Morgan | Overweight |
| 2019-09-03 | 再開されました | Barclays | Overweight |
| 2019-05-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 開始されました | UBS | Buy |
| 2018-10-16 | 開始されました | Barclays | Overweight |
| 2018-10-02 | 繰り返されました | Morgan Stanley | Overweight |
| 2018-09-07 | 繰り返されました | Needham | Strong Buy |
| 2018-09-04 | アップグレード | Jefferies | Hold → Buy |
| 2018-07-06 | 繰り返されました | Needham | Strong Buy |
| 2018-06-27 | 開始されました | Bernstein | Outperform |
| 2018-04-26 | 繰り返されました | Needham | Strong Buy |
すべてを表示
Boston Scientific Corp (BSX) 最新ニュース
Boston Scientific Corporation (BSX)’s Breakthroughs: A Hidden Gem in Billionaire Ken Griffin’s Portfolio - Insider Monkey
Boston Scientific Co. (NYSE:BSX) Stake Boosted by PNC Financial Services Group Inc. - MarketBeat
Boston Scientific Stock Set to Gain From Completion of Axonics Deal - Yahoo Finance
Boston Sci study shows Watchman Flx better OPTION than DOAC - BioWorld Online
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific Completes $3.7B Acquisition of Axonics - Orange County Business Journal
Boston Scientific stock soars to all-time high of $89.33 - Investing.com
Boston Scientific stock soars to all-time high of $89.33 By Investing.com - Investing.com Canada
Here's Why We Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today - Yahoo Finance
Boston Scientific’s Watchman could be new option for patients post ablation: study - Yahoo Finance
Boston Scientific acquires Axonics - Medical Buyer
Boston Scientific reports outcomes from trial of LAAC device - Yahoo Finance
Boston Scientific to Acquire Cortex - Today's Medical Developments
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial - Quantisnow
Boston Scientific (BSX) Completes Acquisition of Axonics - GuruFocus.com
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific put volume heavy and directionally bearish - TipRanks
Boston Scientific Closes $3.7B Deal for Axonics - MPO-mag
Boston Scientific Closes Acquisition of Axonics, Inc. - Quantisnow
Boston Scientific Closes Acquisition of Axonics, Inc. – Company Announcement - Financial Times
Boston Scientific closes $3.7B Axonics deal after lengthy review - Yahoo Finance
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
SoniVie Names Axonics' Raymond Cohen as Chairman Following $3.7B Boston Scientific Deal | BSX Stock News - StockTitan
Boston Scientific Co. (NYSE:BSX) Shares Bought by Huntington National Bank - MarketBeat
Investing in Boston Scientific (NYSE:BSX) three years ago would have delivered you a 113% gain - Yahoo Finance
Urology Devices Market to Surpass Market Valuation of USD 61.62 Billion by 2031 | SkyQuest Technology - Benzinga
Boston Scientific EVP John Sorenson sells $2.68m in stock - Investing.com
Boston Sci charges ahead with AVANT GUARD PFA trial - BioWorld Online
Boston Scientific To Present At 2024 UBS Global Healthcare Conference; Webcast At 10:15 AM ET - Nasdaq
Boston Scientific resumes enrolment in pulsed field ablation trial - Yahoo Finance
BSXBoston Scientific Corp. Latest Stock News & Market Updates - StockTitan
Boston Scientific Corporation (BSX): Among the Best Low Volatility Stocks to Invest In Now - Insider Monkey
Boston Scientific Corporation (BSX): A Hot Growth Stock to Buy According to Hedge Funds - Insider Monkey
Van ECK Associates Corp Has $5.06 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
8 Hot Growth Stocks To Buy According to Hedge Funds - Insider Monkey
Boston Scientific stock soars to all-time high of $88.81 - Investing.com
We Think Boston Scientific's (NYSE:BSX) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Petri Dish: Boston Scientific resumes atrial fibrillation trial; Seaport hires CFO - The Business Journals
Boston Scientific CEO sells shares worth $13.8 million By Investing.com - Investing.com Canada
Boston Scientific CEO sells shares worth $13.8 million - Investing.com
Boston Scientific Corp. stock rises Thursday, still underperforms market - MarketWatch
Boston Scientific (BSX) Resumes AVANT GUARD Clinical Trial for A - GuruFocus.com
Boston Scientific resumes AVANT GUARD trial - Investing.com
Kidney Stone Management Market Forecast Report, 2024-2032Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share - Yahoo Finance
Boston Scientific Resumes AVANT GUARD Clinical Trial - TipRanks
Boston Scientific Corp. stock rises Wednesday, still underperforms market - MarketWatch
Boston Scientific Corp. stock rises Tuesday, still underperforms market - MarketWatch
Boston Scientific to Speak at Conference - Baystreet.ca
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference – Company Announcement - Financial Times
Boston Scientific to bolster cardiac ablation portfolio with Cortex acquisition - Medical Device Network
Heritage Investors Management Corp Sells 7,684 Shares of Boston Scientific Co. (NYSE:BSX) - MarketBeat
Boston Scientific Corp (BSX) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
0.15%
大文字化:
|
ボリューム (24 時間):